A Phase 2, randomized, placebo-controlled, double-blind proof-of-concept study of the efficacy and safety of PF-02545920 in subjects with Huntington’s disease

HS 2014-1584
Huntington’s, Brain & Nerve
Neal S. Hermanowicz, MD
University of California Irvine, in Irvine
The purpose of this research study is to compare the safety, tolerability and effectiveness of two doses of PF-02545920 to placebo on improving voluntary movement and overall symptoms in subjects with Huntington’s disease. A placebo looks like the study drug but does not contain any drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.

You can participate in this study if you:

  • Are 30-65 years of age
  • Diagnosed with Huntington’s disease

You cannot participate in this study if you:

  • Have had deep brain stimulation (DBS)
  • Are pregnant or breastfeeding
This study includes 10 visits and takes about 49 hours over a period of 31 weeks/8 months.
Taking part in this study may or may not make your health better. While researchers hope PF-02545920 will be more effective than the standard (usual) treatment, there is no proof of this yet. This study will help researchers learn more about PF-02545920, and it is hoped that this information will help in the treatment of future patients with conditions like yours.
You will not be compensated for your participation in this research study. For each visit directly related to this study, you will be reimbursed after providing receipts of your travel expenses. If you need to be accompanied to the study visits, your traveling companion may be also reimbursed based on local regulations.
PF-02545920, Pfizer-HD A8241021
Drug therapy
Katrina Samson